ArticleFrontiers in immunology2022
Dominant CD8
Abstract read
In one paragraph
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Fine specificity of antibodies to SARS-CoV-2 nucleoprotein in patients with COVID-19.Immunologic research · 2026Article
- Humoral and functional SARS-CoV-2-specific T-cell responses elicited in chronic lymphocytic leukaemia patients with GEO-CM04S1 a synthetic MVA-vectored COVID-19 vaccine.British journal of haematology · 2026Article
- CEI: A Clonal Expansion Identifier for T-cell receptor clones following SARS-CoV-2 vaccination.ArXiv · 2026Article
- Review
- Direct pharmacological AMPK activation inhibits mucosal SARS-CoV-2 infection by reducing lipid metabolism, restoring autophagy flux and the type I IFN response.Journal of virology · 2025Article
- Structural stabilization of the intrinsically disordered SARS-CoV-2 N by binding to RNA sequences engineered from the viral genome fragment.Nature communications · 2025Article
- Defining the balance between optimal immunity and immunopathology in influenza virus infection.Nature reviews. Immunology · 2024Review
- Evaluation of an RBD-nucleocapsid fusion protein as a booster candidate for COVID-19 vaccine.iScience · 2024Article
- Comparison of Four T-cell Assays and Two Binding Antibody Assays in SARS-CoV-2 Vaccinees With or Without Omicron Breakthrough Infection.Annals of laboratory medicine · 2023Article
- Predominantly defective CD8Journal of translational medicine · 2023Article
- Limited induction of polyfunctional lung-resident memory T cells against SARS-CoV-2 by mRNA vaccination compared to infection.Nature communications · 2023Article
- Employing T-Cell Memory to Effectively Target SARS-CoV-2.Pathogens (Basel, Switzerland) · 2023Review
- The prospect of universal coronavirus immunity: a characterization of reciprocal and non-reciprocal T cell responses against SARS-CoV2 and common human coronaviruses.bioRxiv : the preprint server for biology · 2023Article
- SARS-CoV-2 epitope-specific T cells: Immunity response feature, TCR repertoire characteristics and cross-reactivity.Frontiers in immunology · 2023Review
- Persistent memory despite rapid contraction of circulating T Cell responses to SARS-CoV-2 mRNA vaccination.Frontiers in immunology · 2023Article
- The prospect of universal coronavirus immunity: characterization of reciprocal and non-reciprocal T cell responses against SARS-CoV2 and common human coronaviruses.Frontiers in immunology · 2023Article
- Longitudinal analysis of SARS-CoV-2 infection and vaccination in the LA-SPARTA cohort reveals increased risk of infection in vaccinated Hispanic participants.Frontiers in immunology · 2023Article
- Preliminary Research on the Effect of Hyperbaric Oxygen Therapy in Patients with Post-COVID-19 Syndrome.Journal of clinical medicine · 2022Article
- Production and Characterization of a SARS-CoV-2 Nucleocapsid Protein Reference Material.ACS measurement science au · 2022Article
- Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity.mBio · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Ellie TausDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States.
Christian HofmannDepartment of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States.
Francisco Javier IbarrondoDepartment of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States.
Mary Ann HausnerDepartment of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States.
Jennifer A FulcherDepartment of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States.
Paul KrogstadDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States.
Kathie G FerbasDepartment of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States.
Nicole H TobinDepartment of Pediatrics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States.
Anne W RimoinFielding School of Public Health, University of California Los Angeles, Los Angeles, CA, United States.
Grace M AldrovandiDepartment of Pediatrics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States.
Otto O YangDepartment of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States.
Funding
Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTON, PETER A · 1991 to 2018
$39.9MNIAID NIH HHS P30 AI028697
Abstract
CD8
Indexed as
Antibodies, ViralBroadly Neutralizing AntibodiesCD8-Positive T-LymphocytesCells, CulturedCOVID-19COVID-19 VaccinesEnzyme-Linked Immunospot AssayHumansMolecular Targeted TherapyNucleocapsidPeptidesSARS-CoV-2Spike Glycoprotein, CoronavirusUnited StatesVaccinationAntibodies, ViralBroadly Neutralizing AntibodiesCOVID-19 VaccinesPeptidesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2CD8+ T cellscellular immunityCOVID-19COVID-19 vaccineSARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.